Precision BioSciences, Inc. filings document regulatory disclosures for a clinical-stage gene editing company built around the ARCUS platform and in vivo therapeutic candidates. Recent Forms 8-K furnish operating results, financial-condition updates, business presentations, and Regulation FD materials covering PBGENE-HBV in chronic hepatitis B and PBGENE-DMD in Duchenne muscular dystrophy, including IND-related and clinical-development disclosures.
The company’s proxy materials address board and stockholder meeting matters, executive compensation, equity plans, and governance proposals. Other filing categories cover material agreements, shareholder voting matters, capital-structure disclosures, inducement awards, and forward-looking risk language tied to clinical development, financing capacity, regulatory review, and public-company reporting.
Precision Biosciences, Inc. (DTIL) director Stanley Frankel purchased 1,000 shares of common stock directly on September 28, 2026, at $6 per share. The transaction is described as a purchase in the open market or a private transaction. Afterward, Frankel directly held 41,478 shares. No Rule 10b5-1 plan is reported.
Precision Biosciences Inc. (DTIL) director Melinda Brown purchased 1,135 shares of common stock at $6.27 per share on September 25, 2026. The purchase was reported as an open-market or private transaction. Her directly held position afterward was 45,481 shares, and no Rule 10b5-1 plan is reported.
Precision BioSciences (DTIL) director Geno J. Germano purchased 2,609 shares of common stock on September 25, 2026, at $6.28 per share. The transaction is described as a purchase in the open market or a private transaction. The shares were held directly, and his reported direct holdings after the purchase were 47,492 shares. No Rule 10b5-1 plan is reported.
PRECISION BIOSCIENCES INC (DTIL) received an amended Schedule 13G/A reporting the holdings of Benjamin Weinstein in its common stock.
Weinstein reports 1,105,720 shares beneficially owned, including 203,500 shares issuable upon exercise of warrants, representing 4.01% of the common stock. The percentage is based on 27,601,554 shares outstanding as of August 3, 2026. He reports sole and shared voting and dispositive power over the same 1,105,720 shares and confirms ownership of 5% or less of the class.
Precision BioSciences, Inc. (DTIL) reported that the first patient has been dosed in its Phase 1/2 FUNCTION-DMD clinical trial of PBGENE-DMD, an in vivo gene-editing therapy for Duchenne muscular dystrophy (DMD). The first dosing occurred at Arkansas Children’s Hospital, a specialized Duchenne care center.
PBGENE-DMD uses the company’s ARCUS® platform to excise exons 45-55 of the dystrophin gene via two ARCUS nucleases delivered in a single AAV, aiming to restore a near full-length functional dystrophin protein. The trial is enrolling ambulatory boys aged 2–7 with mutations between exons 45 and 55, a group representing up to 60% of boys with DMD, with initial safety data expected by year-end 2026.
Precision BioSciences is a clinical-stage gene editing company developing in vivo therapies using its proprietary ARCUS platform, led by HBV program PBGENE‑HBV and DMD program PBGENE‑DMD. In the ELIMINATE‑B trial, liver biopsies showed about a 1‑log reduction in cccDNA‑derived transcripts after PBGENE‑HBV dosing, with less than 1% of cccDNA remaining in one patient and cumulative effects with repeat dosing. pgRNA became durably undetectable in all patients who had detectable pgRNA at baseline, with sustained S‑antigen declines and no dose‑limiting toxicities reported across 16 patients.
For the six months ended June 30, 2026, the company reported $10.8 million of revenue, primarily from a $7.5 million milestone under the TG Therapeutics license and a $4.0 million agriculture milestone, versus less than $0.1 million a year earlier. Research and development expenses were $25.5 million and general and administrative expenses $13.6 million, yielding an operating loss of $28.2 million. A large non‑cash loss from remeasurement of warrant liabilities and other fair value items drove total net loss to $51.1 million.
Cash, cash equivalents and restricted cash totaled $112.4 million at June 30, 2026, including $22.5 million held as security for a term loan maturing in 2029. Management states that existing cash, operating discipline and access to an at‑the‑market equity facility are expected to fund operations through 2028.
Precision BioSciences, Inc. reported second quarter 2026 results and highlighted clinical progress in its gene editing pipeline. For the quarter ended June 30, 2026, revenue was $0 and net loss was $32.7 million, or $(1.26) per share, driven largely by a non-cash loss from the change in fair value of warrant liabilities. Research and development expenses were $12.4 million and general and administrative expenses were $6.8 million.
Cash, cash equivalents and restricted cash totaled $112.4 million as of June 30, 2026, which the company expects will fund operations and data milestones for PBGENE-HBV and PBGENE-DMD through 2028. In its ELIMINATE-B trial for chronic hepatitis B, PBGENE-HBV showed biopsy evidence of a 1-log reduction in cccDNA-derived transcripts with less than 1% remaining in one patient and sustained pgRNA loss in 100% of evaluable patients. PBGENE-DMD for Duchenne muscular dystrophy is in a Phase 1/2 trial now recruiting boys ages 2 to 7, with initial safety data targeted by year-end 2026. Partnered programs in OTC deficiency and oncology/multiple sclerosis advanced, and leadership changes were made including appointing Naresh Tanna as Chief Financial Officer. The company also joined the Russell 2000 Index in June 2026.
Precision BioSciences Inc reports that Chief Scientific Officer Cassandra Louise Gorsuch directly owns 16,028 shares of Common Stock, fully vested employee stock options over 235 shares at $36.0000 and 585 shares at $359.4000, and Restricted Stock Units covering 40,000 and 179,340 shares that vest in three substantially equal annual installments beginning in 2026 and 2027, subject to continued service.
Mei Zhang Lu, Chief Accounting Officer of Precision Biosciences Inc, reports direct ownership of 5,115 shares of common stock. She also holds fully vested employee stock options covering 945, 214, 403 and 778 shares at exercise prices of 378.0000, 174.9000, 340.2000 and 122.4000, expiring between 2029 and 2032, plus restricted stock units covering 11,288 and 30,129 shares that vest in three substantially equal annual installments beginning on February 24, 2026 and February 22, 2027, respectively.
Naresh Haresh Tanna, Chief Financial Officer of Precision Biosciences Inc, reports direct ownership of 25,575 shares of common stock. Reported equity awards include RSU grants of 16,683, 33,317, 45,000 and 179,340 units, each vesting in three substantially equal annual installments beginning on January 20, 2025, January 27, 2025, February 17, 2026 and February 19, 2027, respectively, subject to continued service.